Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico
Lisata Therapeutics, a clinical-stage pharmaceutical company focused on innovative therapies for advanced solid tumors, will participate in the Sequire Investor Summit from April 24-26, 2023, at La Concha Resort in San Juan, Puerto Rico. CEO David J. Mazzo will present a company overview on April 25 at 3:00 PM. The event aims to connect emerging companies with investors.
Lisata's lead investigational product, LSTA1, targets novel uptake pathways for anti-cancer drugs, enhancing their delivery to tumors while sparing normal tissues. It has shown favorable safety and activity in clinical trials for pancreatic cancer, and has potential for various treatment modalities, including immunotherapies. The company continues to gather data to support LSTA1's effectiveness against a range of solid tumors.
- None.
- None.
BASKING RIDGE, NJ, April 19, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, announces its participation in the upcoming Sequire Investor Summit to be held April 24-26, 2023, at La Concha Resort in San Juan, Puerto Rico.
David J. Mazzo, PhD, Chief Executive Officer of Lisata, will present a company overview on April 25th at 3:00pm. For more information about the Sequire Investor Summit, including registration details, please visit the official event website at https://puertorico.srax.com/.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s lead investigational product candidate, LSTA1, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors more effectively. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 also has the potential to modify the tumor microenvironment, with the objective of making tumors more susceptible to immunotherapies. LSTA1 has demonstrated favorable safety, tolerability, and activity in clinical trials to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. Lisata and its collaborators have also amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics. Lisata is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively. For more information on the Company, please visit www.lisata.com.
About SRAX
SRAX Inc. is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information on SRAX, visit srax.com and mysequire.com.
Contact:
Investors and Media:
Lisata Therapeutics, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com
FAQ
What is Lisata Therapeutics participating in on April 24-26, 2023?
When will David J. Mazzo present at the Sequire Investor Summit?
What is LSTA1, the investigational product from Lisata Therapeutics?
How does LSTA1 improve treatment for solid tumors?
Where is the Sequire Investor Summit being held?
